Macquarie Group
GLMD icon

Macquarie Group’s Galmed Pharmaceuticals GLMD Stock Holding History

Macquarie Group’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-5
Closed -$8K – 2237
2017
Q4 		$8K Buy
+5
New +$7.39K ﹤0.01% 2305

Other funds holding GLMD

6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Macquarie Group's GLMD Position: Q1 2018 in Review

Macquarie Group sold out of Galmed Pharmaceuticals (GLMD) in Q1 2018, closing a stake of 5 shares — an estimated $8K sold.

Macquarie Group first reported a position in GLMD in Q4 2017 and held it in 1 quarter. The position peaked at $8K in Q4 2017. 19 funds tracked by Wall St. Rank hold GLMD as of Q1 2018.

  • Macquarie Group reported no remaining Galmed Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Macquarie Group sold 5 Galmed Pharmaceuticals shares in Q1 2018, an estimated $8K.
  • Macquarie Group first reported a position in Galmed Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Macquarie Group's Galmed Pharmaceuticals position peaked at $8K in Q4 2017.
  • 19 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q1 2018.

Based on Macquarie Group's 13F filing for Q1 2018, filed 11 May 2018.